RNS Number : 0062M
N4 Pharma PLC
25 April 2024

25 April 2024

N4 Pharma plc
("N4 Pharma" or the "Company")

Collaboration Agreement with SRI International Inc.

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system designed to carry nucleotides to be developed as cancer treatments and vaccines, is delighted to announce that it has entered into a research collaboration agreement (the "Agreement") with SRI International, an independent nonprofit research institute based in Silicon Valley, California ("SRI") to combine Nuvec® with SRI's proprietary FOX Three Molecular Guidance System™ ("MGS") with the aim of co-marketing the resultant combined technology.

Under the Agreement, the Company will collaborate with SRI to perform research to conjugate its MGS system to Nuvec® in order to increase intracellular delivery to specific target cells. On the back of the combined technology, N4 Pharma and SRI will work collaboratively to develop and pursue new business opportunities.

SRI's MGS technology is designed to overcome cellular barriers that prevent intracellular delivery of large molecule biotherapeutics. The system uses proprietary technology that enables the delivery of macromolecular payloads to the target cell and then on to subcellular locations within those cells. SRI has developed a panel of 50 MGSs targeted at a wide variety of cell types, both diseased and healthy.

SRI has demonstrated that the MGS technology can deliver more than a dozen types of payloads - from functional enzymes, antibodies, and nucleic acids (including siRNA, ASOs, and DNA) to liposomes and nanoparticles - to targeted, intracellular molecular-target locations previously considered unreachable, and therefore, untreatable. For more information on MGS see: https://www.sri.com/platform/fox-three-molecular-guidance-system-mgs/.

The SRI Biosciences division the Company will be working with integrates basic biomedical research with drug and diagnostics discovery, and preclinical and clinical development. The team has advanced more than 200 drugs to clinical trials, and 25 have reached the market. The division is focused on novel platforms and programs in a variety of therapeutic areas targeting high unmet medical needs.

Kathlynn Brown, President of SRI's Bioscience Division, commented:

"We're excited to work with N4 Pharma to advance nucleic acid therapies and expand the number of applications of their Nuvec nanoparticle technology using the FOX Three Platform. The key properties of Nuvec, including preventing enzymatic breakdown of nucleotides and large surface area allowing multiple copy number of cargo, together with the targeting provided by MGS, may significantly enhance the use of nucleotide therapies. This partnership marks an exciting journey towards expanding treatment possibilities and transforming the landscape of biomedicine."

Nigel Theobald, Chief Executive Officer of the Company, commented:

"We are delighted to be working with SRI and to have entered into this collaboration agreement. Combining our technologies successfully will lead to working with major pharma companies in the fields of oncology and vaccines with the exciting potential to develop novel products.

"SRI collaborates with a broad range of partners from small and virtual biotechnology companies to top ten pharmaceutical companies and other leading industry partners, which will give us unparalleled access to potential commercial partners on the back of any successful combined technology resulting from our research.

This marks an exciting new chapter for N4 Pharma and I look forward to providing further updates as the research work progresses, as well as on our other work streams such as oral applications of Nuvec® and the development of ECP105 for an orphan indication with Nanogenics."

About SRI

SRI is an independent, global leader in R&D with deep roots in Silicon Valley. It is a nonprofit research institute, headquartered in Menlo Park, Calif., with a rich history of supporting government and industry. Its objective is to

create and deliver world-changing solutions for a safer, healthier, and more sustainable future. For more than 75 years, SRI has collaborated across technical and scientific disciplines to discover and develop groundbreaking products and technologies and bring innovations and ideas to the marketplace. Learn more at www.sri.com.

For more information please contact:

N4 Pharma plc
Nigel Theobald, CEO
Luke Cairns, Executive Director

Via N4 Pharma Investor Hub

Engage with us directly at N4 Pharma Investor Hub

Sign up at investors.n4pharma.com

SP Angel Corporate Finance LLP
Nominated Adviser and Joint Broker
Matthew Johnson/Caroline Rowe/Kasia Brzozowska (Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)

Tel: +44(0)20 3470 0470

Turner Pope Investments (TPI) Limited
Joint Broker
Andy Thacker
James Pope

Tel: +44(0)20 3657 0050

About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for oncology, gene therapy and vaccines using its unique silica nanoparticle delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel antigens in these fields to use Nuvec® as the delivery vehicle for these antigens. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.

For further information on the Company visit www.n4pharma.com or sign up at investors.n4pharma.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

AGRSEMSMIELSEDL